However, there were no significant differences in recurrence rate, risk of AML transformation, treatment response to DEC and median OS (mOS: 628 days and 790 days, p = 0.765) between the U2AF1 mutation and U2AF1 non-mutated groups;. Here, U2AF1 is linked to acute myeloid leukemia.